Results 191 to 200 of about 91,140 (235)
Cost‐effectiveness of a randomized controlled trial comparing low‐dose aspirin to placebo for the prevention of recurrent preterm birth
International Journal of Gynecology &Obstetrics, Volume 169, Issue 1, Page 399-407, April 2025.Abstract
To assess the cost‐effectiveness of low‐dose aspirin compared to placebo for the prevention of recurrent preterm birth from a healthcare perspective. This was a cost‐effectiveness analysis alongside a multicenter, randomized, double‐blinded, placebo‐controlled trial.Anadeijda J. E. M. C. Landman, Hana M. Broulikova, Laura Visser, Tobias A. J. Nijman, Marieke A. C. Hemels, Karin C. Vollebregt, Elisabeth M. A. Boormans, Henk A. Bremer, Esther Tuinman, Josje Langenveld, Flip van der Made, Robbert J. P. Rijnders, Huib A. A. M. van Vliet, Liv M. Freeman, Roel de Heus, Judith Blaauw, Ineke Krabbendam, Rafli van de Laar, Marieke F. G. Verberg, Hubertina C. J. Scheepers, Ben W. Mol, Christianne J. M. de Groot, Martijn A. Oudijk, Judith E. Bosmans, Marjon A. de Boer +24 morewiley +1 more sourceDeep phenotyping of suicidal ideation after discharge from psychiatric inpatient care: study protocol for an interdisciplinary, multicentre prospective observational study in Psychiatric University Hospitals. [PDF]
BMJ OpenMonn A, Homan S, Mocellin J, Raja SM, Kirchhofer L, Walser V, Dolev EL, Nißen M, Kowatsch T, Seiler G, Schultebraucks K, Olbrich S, Kleim B. +12 moreeuropepmc +1 more sourceAdverse outcomes among pregnant women with COVID‐19 according to hospitalization status: A prospective individual participant data meta‐analysis in Europe and North America
International Journal of Gynecology &Obstetrics, EarlyView.Abstract Background
Understanding the varied impact of COVID‐19 severity on pregnancy outcomes is crucial for informed clinical management and targeted interventions. Objective
To evaluate the impact of COVID‐19 on pregnancy outcomes, distinguishing between pregnant women managed in primary care and those requiring hospitalization.Odette de Bruin, Emeline Maisonneuve, Eimir Hurley, Hedvig M. E. Nordeng, Anick Bérard, Odile Sheehy, Padma Kaul, Mayura U. Shinde, Austin Cosgrove, Jennifer G. Lyons, Elizabeth Messenger‐Jones, Maria E. Kempner, Sengwee Toh, Wei Hua, José J. Hernández‐Muñoz, Leyla Sahin, Carolyn E. Cesta, David Hägg, Rosa Gini, Olga Paoletti, Beatriz Poblador‐Plou, Sue Jordan, Clara L. Rodríguez‐Bernal, Francisco Sánchez‐Sáez, Régis Lassalle, Marie‐Agnès Bernard, Fariba Ahmadizar, Guillaume Favre, Alice Panchaud, Kitty W. M. Bloemenkamp, Kelly Plueschke, Corinne de Vries, Satu J. Siiskonen, Miriam C. J. M. Sturkenboom, on behalf of the CONSIGN Collaboration Group, Benjamin P. Geisler, Mark Walker, Steven Hawken, Sasha Bernatsky, Sherif Eltonsy, Emma Hoffman, Andrew B. Petrone, Jolene Mosley, Jenice Ko, Claudia Bartolini, Giuseppe Roberto, Giorgio Limoncella, Anna Girardi, Giulia Hyeraci, Antonio Gimeno‐Miguel, Jonás Carmona‐Pírez, Antonio Poncel‐Falcó, Aida Moreno‐Juste, Alexandra Prados‐Torres, Daniel Thayer, Ian Farr, Saira Ahmed, Ieuan Scanlon, Gabriel Sanfélix‐Gimeno, Isabel Hurtado, Anibal Garcia‐Sempere, Salvador Peiro, Jérémy Jové, Dunia Sakr, Cécile Droz‐Perroteau, Ema Alsina, David Baud, Hilde M. Engjom, Judit Riera‐Arnau, Mònica Sabaté Gallego, Elena Ballarín Alins, Cristina Aguilera Martin, Melissa Kampman, Celline Brasil +73 morewiley +1 more sourceN6‐Methyladenosine (m6A) in Liver Disease: Pathogenic Mechanisms and Therapeutic Potential
iNew Medicine, EarlyView.ABSTRACT
Accumulating evidence highlights the critical role of epigenetic modifications, particularly N6‐methyladenosine (m6A), in liver disease. As the most abundant RNA modification in eukaryotic cells, m6A is dynamically regulated by multicomponent m6A methyltransferases (e.g., METTL3 and METTL14), demethylases (FTO and ALKBH5), and m6A‐binding ...Yingfen Chen, Ru Ya, Ziling Zhang, Siyue Dong, Seol Hee Park, Wonhyo Seo, Yong He +6 morewiley +1 more source